Pacira | PCRX - Loan Capital


Pacira reported $372.19M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Assertio Holdings USD 39.17M 120K Sep/2025
Astellas Pharma JPY 320B 0 Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 294.85M 2.33M Mar/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 39.44B 30M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Omeros USD 403.72M 27.2M Jun/2024
Pacira USD 372.19M 4.53M Dec/2025
Perrigo USD 3.6B 4.5M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Teva Pharmaceutical Industries USD 14.99B 1.78B Dec/2025
Xeris Pharmaceuticals USD 219.47M 839K Sep/2025
Xoma USD 94.38M 7.82M Sep/2025
Zoetis USD 9.04B 1.97B Dec/2025